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Abstract
Background: The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference
(WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral
adipose function and insulin sensitivity. Our aim was to find the optimal cut-off points of VAI identifying a visceral
adipose dysfunction (VAD) associated with cardiometabolic risk in a Caucasian Sicilian population.
Methods: Medical check-up data of 1,764 Primary Care patients (PC patients) were retrospectively and cross-
sectionally examined using a receiver-operating characteristic (ROC) curve to determine appropriate stratified-for-
age cut-off of VAI, for the identification of PC patients with Metabolic Syndrome (MetS) according to the NCEP-ATP
III criteria. The PC patients with higher VAI scores were subdivided into three groups according to VAI tertiles (i.e.
PC patients with mild VAD, moderate VAD or severe VAD). Finally, VAD classes were compared to classical cardio-
and cerebrovascular risk factors as independent predictors of coronary heart disease and/or myocardial infarction,
transient ischemic attack and/or ischemic stroke.
Results: Moderate and severe VADs proved to be independently associated with cardiovascular events [(OR: 5.35;
95% CI: 1.92-14.87; p = 0.001) and (OR: 7.46; 95% CI: 2.64-21.05; p < 0.001) respectively]. Mild, moderate and severe
VADs were found to be independently associated with cerebrovascular events [(OR: 2.73; 95% CI: 1.12-6.65; p =
0.027), (OR: 4.20; 95% CI: 1.86-9.45; p = 0.001) and (OR: 5.10; 95% CI: 2.14-12.17; p < 0.001) respectively].
Conclusions: Our study suggests that among Caucasian Sicilian subjects there are clear cut-off points of VAI able
to identify a VAD strongly associated with cardiometabolic risk.
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Background
The term ‘cardiometabolic risk’ was coined by the
American Diabetes Association [1] and the American
Heart Association [2] to describe the overall risk of
developing type 2 diabetes and cardiovascular diseases.
Abdominal obesity, insulin resistance and ‘dysfunctional’
visceral fat are key components of a constellation of
metabolic abnormalities, related to energy surplus
(resulting from a sedentary lifestyle combined with
excessive calorie consumption), characterizing ‘cardio-
metabolic risk’ [3]. To identify visceral obesity, the clini-
cal parameter most commonly used today is Waist
Circumference (WC). Nevertheless, WC alone does not
help in distinguishing between subcutaneous and visc-
eral (both omental and mesenteric) fat mass [4]. This is
particularly significant given that differences in insulin-
sensitivity, lipolytic activity and adipocytokines produc-
tion play a fundamental role in the genesis of cardiovas-
cular sequelae [5-7]. MRI and CT are now considered
the gold standard for the quantitative evaluation of Visc-
eral Adipose Tissue (VAT) and Subcutaneous Adipose
Tissue (SAT) [8]. Since these two methods are
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cannot be recommended in routinely clinical practice.
Furthermore, in order to predict VAT-associated car-
diometabolic risk, it would be highly desirable to per-
form routine evaluation of “visceral adipose dysfunction”
(VAD) by adipocytokine assessment. This approach,
however, is also unfeasible because of the complexity of
the ‘adipose endocrine organ’ function [9], and again for
the high costs involved.
Recently our research group developed the Visceral
Adiposity Index (VAI), a mathematical model that uses
both anthropometric (body mass index [BMI] and WC)
and functional (triglycerides [TG] and high-density lipo-
protein [HDL] cholesterol) simple parameters [10]. This
index, which could be considered a simple surrogate
marker of VAD, showed a strong association with both
the rate of peripheral glucose utilization (M value) dur-
ing the Euglycemic-hyperinsulinemic Clamp and with
visceral adipose tissue (VAT) measured with MRI.
Furthermore, it showed a strong independent associa-
tion with both cardiovascular and cerebrovascular events
[10] and showed better predictive power for incident
diabetes events than its individual components (WC,
BMI, TG and HDL) [11]
Moreover, this index has been studied in specific popu-
lations of patients: in a specific cohort of patients with
genotype 1 chronic hepatitis C, VAD identified by a
higher VAI score proved to be independently associated
with both steatosis and necroinflammatory activity and
directly correlated with viral load [12]; in a specific
cohort of women with polycystic ovary syndrome
(PCOS) it has proved to be an easy and useful tool for
the assessment of cardiometabolic risk associated with
the oligomenorrhoic phenotype of PCOS [13].
This cross-sectional retrospective study therefore had
a 2-fold objective:
1) to identify in a Caucasian Sicilian population,
stratified for age, VAI cut-off points strongly asso-
ciated with Metabolic Syndrome (MetS) using the
receiver operating characteristic (ROC) curve
analysis;
2) to examine the relationship between this surro-
gate and indirect VAD measure and cardio- and cer-
ebrovascular events.
Methods
This retrospective cross-sectional study was performed
in collaboration with 10 National Health Service Pri-
mary Care Physicians (PCPs) on 13,195 individuals from
the town of Alcamo, in Western Sicily (The AlkaMesy
Study) as previously described [10]. Since data from the
13,195 Primary Care patients (PC patients) were
recorded anonymously, no individual informed consent
was needed. The study was approved by the Institutional
Review Board of the Faculty of Medicine, University of
Palermo, given that the identity of the participants
remained anonymous during database analysis.
Data Collection
Data have been recorded by PCPs since 1996 using the
Millewin computed medical chart (v. 13.35.1054,
Gruppo Dedalus Millenium srl; Florence, Italy).
For 1,764 of the 13,195 PC patients, complete infor-
mation was available on the following aspects: age, sex,
smoking habits, WC (cm), BMI (kg/m
2), age of first
heart and/or cerebrovascular event, diagnosis of diabetes
mellitus according to the American Diabetes Association
[14], presence of high blood pressure according to ESH/
ESC criteria [15], dyslipidemia as defined by NCEP ATP
III [16], coronary heart disease (CHD) and/or myocar-
dial infarction (MI) and transient ischemic attack (TIA)
and/or ischemic stroke (IS). This group (585 males and
1,179 females; mean age 47.80 ± 18.28, range 16-99
years) was selected for cross-sectional analysis; the num-
ber of selected PC patients was adequate to evaluate
two-tailed hypotheses regarding differences in the para-
meters investigate between the subgroups (PC patients
with VAD and without VAD) in the study greater than
0.5 standard deviations, achieving statistical power
greater than 0.80 at 5% probability level (p-value).
With regard to the clinical and biochemical parameters
analyzed, we used the mean value of data recorded in the
last six months of follow-up. For patients who experi-
enced cardio- and/or cerebrovascular accident, we used
the mean value of data recorded in the six months before
the event. Subjects who had had a cardio- and/or cere-
brovascular event before 1996 (i.e. before the Mille win
computed medical chart was used) were excluded
because data were not available at the time of the event.
WC was measured at the midpoint between the lower
rib and the iliac crest. Blood chemistry analyses were
performed in accredited laboratories of the National
Health Service in Alcamo.
LDL cholesterol was calculated using the Friedwald
equation. Glomerular Filtration Rate (GFR) was esti-
mated from serum creatinine using the MDRD formula
and was expressed as ml/min/1.73 m
2 [17].
VAI score was calculated as described [10] using the
following sex-specific equations, when TG is Triglycer-
ides levels expressed in mmol/l and HDL is HDL-Cho-
lesterol levels expressed in mmol/l:
Males : VAI =

WC
39.68 + (1.88 × BMI)

×

TG
1.03

×

1.31
HDL

Females : VAI =

WC
36.58 + (1.89 × BMI)

×

TG
0.81

×

1.52
HDL

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The Statistical Packages for Social Sciences SPSS version
17 and MedCalc version 11.3 were used for data analy-
sis. Baseline characteristics were presented as mean ±
Standard Deviation (SD) for continuous variables; rates
and proportions were calculated for categorical data.
Normality of distribution for quantitative data was
assessed by the Kolmogorov-Smirnov test. Because
HbA1c did not present normal distribution, it was
therefore log-transformed. Receiver-operating character-
istic (ROC) curve analyses were performed to determine
appropriate cut-off points of VAI in identifying PC
patients with MetS. Differences between groups in uni-
variate analysis were detected by the unpaired Student’s
t test for continuous variables and by the c
2-test and
Fisher’s exact test (when appropriate) for categorical
variables. The Anova trend analysis and the c
2-test for
trend were used to assess means and proportions of the
population characteristics across the four PC patient
groups (VAD absent, Mild VAD, Moderate VAD, Severe
VAD). Multiple logistic regression models were per-
formed to explore possible determinants of cardio- and
cerebrovascular events using two predictive models for
dichotomic variables: “coronary heart disease (CHD) or
myocardial infarction (MI)” and “transient ischemic
attack (TIA) or ischemic stroke (IS)”.
Variables associated with the dependent variable on
univariate analysis (probability threshold, p ≤ 0.10) were
included in two multivariate regression models.
In the first model the following independent variables
were included: Age and Total Cholesterol as continuous
variables; gender (female = 0; male = 1), smoking (never
smoker = 0; current/former smoker = 1), VAD cate-
gories (absent = 0; mild = 1; moderate = 2; severe = 3),
MetS (absent = 0; present = 1), diabetes mellitus/FPG >
5.6 mmol/l (absent = 0; present = 1), high blood pres-
sure (absent = 0; present = 1) as categorical (dichotomic
and ordinal) variables. In the second model the follow-
ing independent variables were included: age and GFR
as continuous variables; gender (female = 0; male = 1),
VAD categories (absent = 0; mild = 1; moderate = 2;
severe = 3), MetS (absent = 0; present = 1), diabetes
mellitus/FPG > 5.6 mmol/l (absent = 0; present = 1),
high blood pressure (absent = 0; present = 1) as catego-
rical (dichotomic and ordinal) variables. To avoid effects
of multicollinearity with VAD categories the variables
High Tryglicerides, Low Hdl Cholesterol, Increased WC
a n dB M Iw e r en o ti n c l u d e di ne i t h e rr e g r e s s i o nm o d e l .
A P value of <0.05 was considered statistically
significant.
Results
The 1,764 PC patients (585 males and 1,179 females;
mean age 47.80 ± 18.28, range 16-99 years; mean BMI
24.27 ± 4.03; mean WC 84.70 ± 11.92) were subdivided
into age quintiles in order to identify optimal age-strati-
fied cut-off points of VAI identifying the presence of
MetS. Optimal VAI cut-off points were: 2.52 (age < 30
years), 2.23 (age ≥ 30 and < 42 years), 1.92 (age ≥ 42
and < 52 years), 1.93 (age ≥ 52 and < 66 years) and 2.00
(age ≥ 66 years) (Table 1, Figure 1). The PC patients
who had a VAI score over the age-stratified cut-off
points were 402 (22.78%). This group was divided into
VAI tertiles as shown in Figure 2. The 1,362 PC patients
with VAI less than or equal to age-stratified cut-off
points were defined “with VAD absent”;i nt h er e m a i n -
ing 402 subjects, the first VAI tertile of PC patients was
defined “with mild VAD”, the second tertile “with mod-
erate VAD” a n dt h et h i r dt e r t i l e“with severe VAD”
(Table 2).
A significant increasing trend between the four groups
of PC patients (PC patients with absent VAD, mild
VAD, moderate VAD and severe VAD) was observed
for age (p < 0.001), BMI (p < 0.001), WC (p < 0.001),
fasting glucose (p < 0.001), ALT (p = 0.002), total cho-
lesterol (p < 0.001) and LDL cholesterol (p < 0.001).
The prevalence of patients with MetS, diabetes, high
blood pressure, low HDL cholesterol, high triglycerides,
CHD and/or MI, TIA and/or IS, increased significantly
across the four groups (p < 0.001 for all variables). A
significant reducing trend was seen for GFR (p < 0.001)
(Table 2). To validate VAD classes as potential indica-
tors of visceral fat dysfunction associated with cardio-
vascular (CHD and/or MI) and cerebrovascular events
(TIA and/or ischemic stroke), data from the 1,764 PC
patients were analyzed using two binary logistic regres-
sion models (Table 3). Among all independent variables
examined moderate VAD (OR = 5.35; 95% CI: 1.92 -
14.87; p = 0.001), severe VAD (OR = 7.46; 95% CI: 2.64
- 21.05; p < 0.001), age at the time of event (OR = 1.06;
95% CI: 1.03 - 1.08; p < 0.001), smoking (OR = 3.34;
95% CI: 1.54 - 7.24; p = 0.002) and male gender (OR =
2.95; 95% CI: 1.33 - 6.54; p = 0.007) were independently
correlated with cardiovascular events (CHD and/or MI).
With regard to cerebrovascular events (TIA and/or IS),
mild VAD (OR = 2.73; 95% CI: 1.12 - 6.65; p = 0.027),
moderate VAD (OR = 4.20; 95% CI: 1.86 - 9.45; p =
0.001), severe VAD (OR = 5.10; 95% CI: 2.14 - 12.17; p
< 0.001), age at time of event (OR = 1.07; 95% CI: 1.05
- 1.10; p < 0.001), male gender (OR = 2.47; 95% CI:
1.32 - 4.63; p = 0.005) showed an independent associa-
tion; a weak inverse independent association was found
with GFR (OR = 0.98; 95% CI: 0.97 - 1.00; p = 0.047)
(Table 3).
Discussion
In our previous study we suggested that a high VAI
score is associated with cardiovascular and
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cardiometabolic risk [10]. However, given the lack of a
prospective longitudinal study, it was not possible to
define irrefutably a high VAI score as a cardiovascular
risk factor. In fact, the cross-sectional nature of the
study has not made it possible to find causal inferences
regarding the relationship between VAI and cardio- and
cerebrovascular events.
In this study we identified in a Caucasian Sicilian
population the age-stratified cut-off points of VAI which
proved to be strongly associated with MetS. The appro-
priate cut-off points of VAI for detecting MetS were
2.52 for PC patients under 30 years, 2.23 for those aged
between 30 and 42 years, 1.92 between 42 and 52 years,
1.93 between 52 and 66 years and 2.00 for PC patients
over 66 years.
PC patients with VAI scores greater than these cut-off
points were arbitrarily defined as having mild, moderate
or severe visceral adipose dysfunction (VAD).
Since visceral fat is universally claimed to be more
strongly associated with cardiometabolic risk than sub-
cutaneous fat, we believe that emphasis should be given
to the new model represented by VAD, since it is widely
reported that visceral fat is more strongly associated
Table 1 Optimal cut-off points of VAI (stratifying PC Patients for age quintiles) to detect subjects with Metabolic
Syndrome (ATP III criteria).
Cutoff Point Sens. (%) Spec. (%) Area under ROC curve SE 95% CI p
First age quintile
Age (< 30 years)
2.52 100 99.45 0.997 0.003 0.98 - 1.00 < 0.001
Second age quintile
Age (≥ 30 and < 42 years)
2.23 84.62 92.39 0.898 0.061 0.86 - 0.92 < 0.001
Third age quintile
Age (≥ 42 and < 52 years)
1.92 90.48 72.55 0.852 0.037 0.80 - 0.88 < 0.001
Fourth age quintile
Age (≥ 52 and < 66 years)
1.93 77.22 82.29 0.840 0.028 0.79 - 0.87 < 0.001
Fifth age quintile
Age (≥ 66 years)
2.00 68.5 76.0 0.783 0.025 0.73 - 0.82 < 0.001
Sens. (sensitivity); Spec. (Specificity); SE (Standard Error). CI (Confidence Interval)
Figure 1 Age-stratified cut-off points of VAI for identification of PC patients with Metabolic Syndrome according to the NCEP-ATP III
criteria.
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fat [18,19] and that VAT remains confirmed as an
important correlate of metabolic risk factors after
accounting for BMI [18,20]. Furthermore, over the last
decade there has been increasing evidence regarding the
endocrine function of adipose tissue: changes in the
secretory function of adipocytes and macrophages,
together with chronic, low-grade inflammation, are asso-
ciated with insulin resistance, dyslipidemia, diabetes
and/or vascular disease, contributing to the clinical
effects of obesity [21-23].
PC patients with VAD ranging from mild to severe,
showed a significant trend of increased prevalence of all
components of the MetS and of cardio- and cerebrovas-
cular events. A significant increased trend for age, fast-
ing glucose, ALT, total cholesterol, TG and HDL was
also observed.
Moderate and severe VAD proved to be independently
associated with cardiovascular (CHD and/or MI) events,
together with smoking, male gender and age at the time
of events, when compared with other conventional
dichotomic risk factors, such as diabetes mellitus/FPG >
5.6 mmol/l, high blood pressure, total cholesterol and
MetS. Furthermore, only mild, moderate and severe
VAD together with male gender and age at the time of
events proved to be independently associated with cere-
brovascular (TIA and/or IS) events.
Surprisingly, VAD was independently associated with
cardio- and cerebrovascular events, but not with MetS
diagnosed according to the ATP III criteria. A possible
explanation might lie in the fact that the 5 variables pro-
posed in the ATP III criteria are not used as quantita-
tive continuous variables, but rather as dichotomous
variables. Thus, such screening tools might prove to be
less efficient for the optimal assignment of a patient
with cardiometabolic risk related to his/her visceral obe-
sity. Indeed, the ‘presence’ or the ‘absence’ of an
abnormality may be too crude to identify the individual
risk profile. Lastly, with current Mets diagnosis criteria,
tools are considered as a homogeneous entity, which is
very unlikely, especially as regards diabetes and high
blood pressure [24,25].
For VAI, which represents a global calculator of non-
glycemic and non-hemodynamic components of the
MetS, while on one hand the variables are treated as
continuous variables, on the other two important
aspects are taken into consideration, i.e. BMI and gen-
der. In fact, women have, on average, more subcuta-
neous fat and less visceral fat than men [26].
Although VAI cannot be claimed per se as a diagnos-
tic tool for cardiovascular and cerebrovascular events,
since it includes physical (BMI and WC) and metabolic
(TG and HDL) parameters, it may, however, indirectly
reflect other non-classical risk factors, i.e. altered pro-
duction of adipocytokines, increased lipolytic activity
and plasma-free fatty acids. In fact, visceral obesity and
“High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia”
were proposed by Unger et al. [27], who suggested that
Figure 2 Subdivision of 1,764 PC patients according to identified cut-off points of VAI and age quintiles.
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subjects with visceral obesity compared with generalized
obesity. This condition, which we ourselves consider
useful to define visceral fat dysfunction, when associated
with physiological age-linked leptin resistance, leads to
pancreatic lipotoxicity with subsequent beta-cell apopto-
sis and diabetes onset, muscle insulin resistance, liver
insulin resistance and NAFLD, lipotoxic cardiomyopathy
and generalized endothelial dysfunction [27].
Conclusion
In conclusion, given the simplicity of WC and BMI
measurement and TG and HDL assessment, and the
identification of reference cut-off points in a Caucasian
population, we suggest that VAI would be an easy tool
for the assessment of VAD, and might be useful in daily
clinical practice and in population studies for the assess-
ment of cardiometabolic risk associated with visceral
obesity.
Table 2 Features of 1,764 PC patients grouped according to VAD classes.
PC patients with
VAD absent
No 1362
PC patients with
Mild VAD
No 126
PC patients with
Moderate VAD
No 141
PC patients with
Severe VAD
No 135
p
§
Females/Males 903/459 84/42 102/39 90/45 0.427
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (years) 44.46 ± 17.80 58.81 ± 14.56 59.22 ± 15.32 59.28 ± 15.38 < 0.001
BMI (Kg/m
2) 23.71 ± 3.62 26.14 ± 4.68 25.92 ± 4.86 26.53 ± 4.61 < 0.001
WC (cm) 82.73 ± 10.76 90.94 ± 12.51 90.65 ± 13.89 92.52 ± 13.09 < 0.001
No (%) No (%) No (%) No (%)
Metabolic Syndrome* 62 (4.6) 40 (31.7) 52 (36.9) 88 (65.2) < 0.001
Diabetes or fasting glucose ≥ 5.6 mmol/l 184 (13.5) 43 (34.1) 41 (29.1) 52 (38.5) < 0.001
Only diabetes 64 (4.7) 22 (17.5) 22 (15.6) 29 (21.5) < 0.001
High Blood pressure 262 (19.2) 55 (43.7) 62 (44) 73 (54.1) < 0.001
High Triglycerides 31 (2.3) 41 (32.5) 80 (56.7) 123 (91.1) < 0.001
Low HDL Cholesterol 215 (15.8) 50 (39.7) 81 (57.4) 92 (68.1) < 0.001
Increased WC 165 (12.1) 38 (30.29) 49 (34.8) 54 (40.0) < 0.001
Classes of obesity**
Underweight 16 (1.2) 1 (0.8) 1 (0.7) - 0.178
Normal weight 1052 (77.2) 68 (54) 75 (53.2) 67 (49.6) < 0.001
Overweight 209 (15.3) 39 (31) 42 (29.8) 45 (33.3) < 0.001
Obese class I 65 (4.8) 10 (7.9) 16 (11.3) 18 (13.3) < 0.001
Obese class II 19 (1.4) 7 (5.6) 6 (4.3) 2 (1.5) 0.082
Obese class III 1 (0.1) 1 (0.8) 1 (0.7) 3 (2.2) < 0.001
CHD or MI 13 (1) 7 (5.6) 10 (7.1) 14 (10.4) < 0.001
TIA or IS 21 (1.5) 9 (7.1) 14 (9.9) 15 (11.1) < 0.001
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Fasting glucose (mmol/l) 5.11 ± 1.26 5.71 ± 1.66 5.59 ± 1.77 5.80 ± 2.37 < 0.001
AST (UI/l) 21.46 ± 19.45 24.03 ± 17.85 20.11 ± 6.39 25.48 ± 22.39 0.104
ALT (UI/l) 20.99 ± 11.69 24.45 ± 17.33 20.32 ± 7.80 25.52 ± 19.24 0.002
GFR (ml/min/1.73 m
2)*** 73.11 ± 25.78 65.14 ± 25.79 60.19 ± 33.65 64.53 ± 32.29 < 0.001
Total Cholesterol (mmol/l) 4.88 ± 0.75 5.12 ± 0.94 5.35 ± 0.99 5.51 ± 0.95 < 0.001
HDL cholesterol (mmol/l) 1.41 ± 0.24 1.25 ± 0.22 1.18 ± 0.22 1.10 ± 0.23 < 0.001
Triglycerides (mmol/l) 0.99 ± 0.31 1.56 ± 0.32 1.78 ± 0.38 2.72 ± 0.97 < 0.001
LDL Cholesterol (mmol/l)**** 3.01 ± 0.69 3.15 ± 0.86 3.35 ± 0.91 3.16 ± 0.97 < 0.001
HbA1c (%) Only in subgroup of diabetic patients 6.45 ± 1.40 7.04 ± 1.45 6.79 ± 1.18 7.48 ± 1.50 0.361
* According to Adult Treatment Panel (ATP) III criteria; ** WHO classification; *** Calculated by Modification of Diet in Renal Disease (MDRD) equation;****
Calculated by Friedewald formula.
§ p value for trend
VAD (visceral adipose dysfunction), BMI (body mass index), WC (waist circumference), HDL (high-density lipoprotein), LDL (low-density lipoprotein), CHD (coronary
heart disease), MI (myocardial infarction), TIA (transiet ischemic attack), IS (ischemic stroke), AST (aspartate transaminase), ALT (alanine transaminase)
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heart disease (CHD) and/or myocardial infarction (MI)” and “Transient ischemic attack (TIA) and/or Ischemic Stroke
(IS)” in 1,764 PC patients.
Coronary Heart Disease (CHD) and/or Myocardial Infarction (MI)
PCP
Without CHD/MI
No 1720
PCP
With CHD/MI
No 44
Univariate
analysis
Multivariate Analysis
Mean ± SD Mean ± SD p p OR (IC 95%)
Age (years) 47.15 ± 17.98 67.64 ± 10.90 < 0.001 < 0.001 1.06 (1.03 - 1.08)
BMI 24.21 ± 4.00 26.70 ± 4.46 < 0.001 - -
Total Cholesterol 4.97 ± 0.83 5.33 ± 0.87 0.005 0.774 1.05 (0.73 - 1.52)
GFR (ml/min/1.73 m
2) 71 ± 27.13 65.06 ± 34.55 0.155 - -
No (%) No (%)
Gender Females Males 1160 (67.4) 560
(32.6)
19 (43.2) 25
(56.8)
0.001 0.007 2.95 (1.33 - 6.54)
Current or former smoker 520 (32.1) 24 (61.5) < 0.001 0.002 3.34 (1.54 - 7.24)
VAD absent Mild VAD Moderate VAD Severe
VAD
1349 (78.4)
119 (6.9)
131 (7.6)
121 (7)
13 (29.5)
7 (15.9)
10 (22.7)
14 (31.8)
< 0.001 0.158 0.001
<0.001
2.37 (0.71 - 7.88)
5.35 (1.92 -
14.87)
7.46 (2.64 -
21.05)
Metabolic Syndrome 220 (12.8) 22 (50) < 0.001 0.581 1.36 (0.45 - 4.11)
Diabetes or fasting glucose ≥ 5.6 mmol/l 303 (17.6) 17 (38.6) < 0.001 0.403 0.678 (0.27 -
1.68)
High Blood pressure 424 (24.7) 28 (63.6) < 0.001 0.278 1.61 (0.68 - 3.83)
High Triglycerides 259 (15.1) 16 (36.4) < 0.001 - -
Low HDL Cholesterol 405 (23.5) 33 (75) < 0.001 - -
Increased WC 290 (16.9) 16 (36.4) 0.001 - -
Transient ischemic attack (TIA) and/or Ischemic Stroke (IS)
PCP
Without TIA/IS
No 1705
PCP
With TIA/IS
No 59
Univariate
analysis
Multivariate Analysis
Mean ± SD Mean ± SD p p OR (IC 95%)
Age (years) 46.84 ± 17.73 71.91 ± 11.11 < 0.001 < 0.001 1.07 (1.05 - 1.10)
BMI 24.24 ± 4.02 25.25 ± 4.32 0.058 - -
Total Cholesterol 4.98 ± 0.83 5.02 ± 0.81 0.762 - -
GFR (ml/min/1.73 m
2) 71.38 ± 27.20 55.75 ± 27.43 < 0.001 0.047 0.98 (0.97 - 1.00)
No (%) No (%)
Gender Females Males 1146 (67.2)
559 (32.8)
33 (55.9)
26 (44.1)
0.070 0.005 2.47 (1.32 - 4.63)
Current or former smoker 525 (32.7) 19 (36.5) 0.561 - -
VAD absent Mild VAD Moderate VAD Severe
VAD
1341 (78.7)
117 (6.)
127 (7.4)
120 (7)
21 (35.6)
9 (15.3)
14 (23.7)
15 (25.4)
< 0.001 0.027 0.001 <
0.001
2.73 (1.12 - 6.65)
4.20 (1.86 - 9.45)
5.10 (2.14 -
12.17)
Metabolic Syndrome 215 (12.6) 27 (45.8) < 0.001 0.634 0.813 (0.34 -
1.90)
Diabetes or fasting glucose ≥ 5.6 mmol/l 295 (17.3) 25 (42.4) < 0.001 0.584 1.21 (0.60 - 2.44)
High Blood pressure 411 (24.1) 41 (69.5) < 0.001 0.078 1.89 (0.93 - 3.83)
High Triglycerides 249 (14.6) 26 (44.1) < 0.001 - -
Low HDL Cholesterol 401 (23.5) 37 (62.7) < 0.001 - -
Increased WC 289 (17) 17 (28.8) 0.018 - -
Univariate analysis: qualitative variables were analyzed through c
2 test or Fisher exact Test; quantitative variables were analyzed through Student’s t Test.
Independent variables showing p value ≤ 0.10 in univariate analysis were entered in multivariate analysis. To avoid effects of multicollinearity with VAD
categories the variables High Triglycerides, Low HDL Cholesterol, Increased WC and BMI were not included in either regression model.
PCP (primary care patients), VAD (visceral adipose dysfunction), GFR (Glomerular filtration rate) BMI (body mass index), WC (waist circumference), HDL (high-
density lipoprotein), CHD (coronary heart disease), MI (myocardial infarction), TIA (transiet ischemic attack), IS (ischemic stroke).
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